Evidence for a role of splanchnic somatostatin in the homeostasis of ingested nutrients.

Somatostatin was infused via the portal vein at a rate of 50 ng/min in a group of eight conscious dogs beginning 30 min before and continuing for 6 h after the ingestion of an 800-g fat-protein meal. The fasting and postprandial levels of plasma somatostatin-like immunoreactivity (SLI), insulin, glucagon, and triglycerides were compared with those during an intraportal infusion of saline as a control. In both groups, SLI rose significantly within 15 min of the ingestion of the meal, but during somatostatin infusion, mean peripheral vein levels of SLI ranged from 30-85 pg/ml above those of the saline control experiments. The postprandial rise in plasma triglycerides was reduced significantly below the control values at all points between 75-270 min, and this reduction was the result of lowered chylomicron levels. Neither fasting nor postprandial insulin or glucagon levels were significantly reduced by the somatostatin infusion. Intraportally infused somatostain also reduced portal vein xylose levels after an intragastric xylose load. The results are compatible with, but do not prove, a physiological role for somatostatin in the homeostasis of ingested nutrients.

[1]  R. Unger,et al.  The response of plasma somatostatin-like immunoreactivity to nutrients in normal and alloxan diabetic dogs. , 1978, Endocrinology.

[2]  L. Orci,et al.  Studies of the physiology and pathophysiology of the pancreatic D cell. , 1978, Metabolism: clinical and experimental.

[3]  R. Unger,et al.  Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog. , 1978, The Journal of clinical investigation.

[4]  R. Unger,et al.  Measurements of somatostatin-like immunoreactivity in plasma. , 1978, Clinica chimica acta; international journal of clinical chemistry.

[5]  J. Oliver,et al.  INHIBITION OF CHOLECYSTOKININ-PANCREOZYMIN RELEASE BY SOMATOSTATIN , 1977, The Lancet.

[6]  L. Orci,et al.  Hypothesis: physiologic role of pancreatic somatostatin and the contribution of D-cell disorders to diabetes mellitus. , 1977, Life sciences.

[7]  P. Bayer,et al.  [Inhibition of postprandial increase in serum triglycerides by somatostatin in man (author's transl)]. , 1977, Wiener klinische Wochenschrift.

[8]  G. Boden,et al.  Effect of Somatostatin on Meal-stimulated Pancreatic Exocrine Secretions in Dogs , 1977, Diabetes.

[9]  P. Felig,et al.  INFLUENCE OF SOMATOSTATIN ON CARBOHYDRATE DISPOSAL AND ABSORPTION IN DIABETES MELLITUS , 1976, The Lancet.

[10]  S. Grundy,et al.  Chylomicron clearance in normal and hyperlipidemic man. , 1976, Metabolism: clinical and experimental.

[11]  M. Berelowitz,et al.  A RADIOIMMUNOASSAY FOR GROWTH HORMONE RELEASE‐INHIBITING HORMONE: METHOD AND QUANTITATIVE TISSUE DISTRIBUTION , 1976, Clinical endocrinology.

[12]  J. Brown,et al.  The effect of somatostatin on release and insulinotropic action of gastric inhibitory polypeptide. , 1975, Canadian journal of physiology and pharmacology.

[13]  O. Owen,et al.  Somatostatin suppresses secretin and pancreatic exocrine secretion , 1975, Science.

[14]  A. Kastin,et al.  Proceedings: Effect of somatostatin on motilin levels and gastric emptying. , 1975, Gut.

[15]  A. Kastin,et al.  DIRECT INHIBITION OF GASTRIC ACID AND PEPSIN SECRETION BY GROWTH-HORMONE RELEASE-INHIBITING HORMONE IN CATS , 1975, The Lancet.

[16]  A. Schally,et al.  Radioimmunoassay for GH-Release Inhibiting Hormone 1 , 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  S. Berson,et al.  Immunoassay of Endogenous Plasma Insulin in Man , 1960 .

[18]  E. Rice,et al.  A photometric method for the determination of free pentoses in animal tissues. , 1948, The Journal of biological chemistry.